You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR METOPROLOL SUCCINATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for METOPROLOL SUCCINATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00077948 ↗ Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure Terminated AstraZeneca Phase 3 2003-07-01 Beta-blocker medications have been shown to improve heart function and prolong the lives of patients with chronic heart failure (CHF). Some people with advanced CHF have difficulty taking beta-blocker medications due to troublesome side effects, such as low blood pressure and/or low heart rate, severe tiredness, dizziness, or shortness of breath. In other words, they have difficulty tolerating beta-blocker medications. The purpose of this study is to determine if enoximone can improve a patient's ability to tolerate a beta-blocker medication.
NCT00077948 ↗ Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure Terminated Gilead Sciences Phase 3 2003-07-01 Beta-blocker medications have been shown to improve heart function and prolong the lives of patients with chronic heart failure (CHF). Some people with advanced CHF have difficulty taking beta-blocker medications due to troublesome side effects, such as low blood pressure and/or low heart rate, severe tiredness, dizziness, or shortness of breath. In other words, they have difficulty tolerating beta-blocker medications. The purpose of this study is to determine if enoximone can improve a patient's ability to tolerate a beta-blocker medication.
NCT00123903 ↗ COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria Terminated GlaxoSmithKline Phase 3 2005-07-01 This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.
NCT00166400 ↗ A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation. Completed AstraZeneca Phase 4 2004-07-01 Mitral valve regurgitation (leakage of the mitral valve of the heart) is frequent and currently there is no specific medical therapy. Mitral regurgitation is a slowly progressive disease that frequently requires surgical treatment. This randomized clinical trial will use Metoprolol, a common beta-blocker medication, to determine if medical treatment impacts mitral valve disease progression.
NCT00166400 ↗ A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation. Completed Mayo Clinic Phase 4 2004-07-01 Mitral valve regurgitation (leakage of the mitral valve of the heart) is frequent and currently there is no specific medical therapy. Mitral regurgitation is a slowly progressive disease that frequently requires surgical treatment. This randomized clinical trial will use Metoprolol, a common beta-blocker medication, to determine if medical treatment impacts mitral valve disease progression.
NCT00255502 ↗ 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects Completed AstraZeneca Phase 3 2002-07-01 This was a 52-week, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of TOPROL-XL (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects. The study population included school age children (age 6 to 12 years < Tanner Stage 3) and adolescents (> 12 years old or > Tanner Stage 3 to 16 years old) of both genders. Because response to some therapies in adult hypertension appears to be different in black and non-black populations, the recruitment will have a mixture of black and non-black subjects. Pharmacokinetic measurements were performed on a subset of patients. Thirty subjects (15 subjects each in the 6 to 12 year age group and the 13 to 16 year age group) had a series of blood samples drawn. All subjects had a trough plasma level taken 24 hours after the last dose of open-label metoprolol CR/XL (Visit 18) with the exception of those subjects who completed Protocol 307B (16 week open-label treatment).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for METOPROLOL SUCCINATE

Condition Name

Condition Name for METOPROLOL SUCCINATE
Intervention Trials
Hypertension 21
Heart Failure 7
Healthy 3
Heart Failure With Preserved Ejection Fraction 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for METOPROLOL SUCCINATE
Intervention Trials
Hypertension 23
Heart Failure 12
Cardiomyopathies 6
Heart Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for METOPROLOL SUCCINATE

Trials by Country

Trials by Country for METOPROLOL SUCCINATE
Location Trials
United States 161
China 28
Canada 17
India 5
Denmark 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for METOPROLOL SUCCINATE
Location Trials
New York 11
Pennsylvania 9
Utah 8
Florida 7
California 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for METOPROLOL SUCCINATE

Clinical Trial Phase

Clinical Trial Phase for METOPROLOL SUCCINATE
Clinical Trial Phase Trials
Phase 4 25
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for METOPROLOL SUCCINATE
Clinical Trial Phase Trials
Completed 34
Terminated 9
Not yet recruiting 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for METOPROLOL SUCCINATE

Sponsor Name

Sponsor Name for METOPROLOL SUCCINATE
Sponsor Trials
AstraZeneca 10
Forest Laboratories 7
GlaxoSmithKline 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for METOPROLOL SUCCINATE
Sponsor Trials
Other 74
Industry 41
NIH 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.